Close Menu

EML4-ALK fusion

A study presented at the AACR meeting showed that Resolution's ctDx-Lung assay reported more oncogenic fusions than Guardant360 in NSCLC patients.

Pfizer's Xalkori yielded significantly longer progression-free survival than standard chemotherapy in the Phase III trial of first-line treatment of ALK-positive NSCLC.